Trial · NCT06118398
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Expanded Disability Status Scale (EDSS) score from baseline. | 1 month | Change in Expanded Disability Status Scale (EDSS) score from baseline to 1 month after treatment (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Change in Expanded Disability Status Scale (EDSS) score from baseline. | 3 months, 6 months | Change in Expanded Disability Status Scale (EDSS) score from baseline to 3 months, 6 months after treatment (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Percentage of Participants with Disability Improvement | 1 month, 3 months, 6 months | Disability improvement is defined as a reduction in EDSS score of: A) ≥1.0 point from the baseline EDSS score when the baseline score was ≤5.5; B) ≥0.5 point when the baseline EDSS score \> 5.5(EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Change in modified Rankin score (mRS) from baseline. | 1 month, 3 months, 6 months | Change in modified Rankin score (mRS) from baseline at 1 month 1, 3 month 3 and 6 month (mRS: Minimum Score 0, Maximum score 6, higher scores mean a worse outcome). |
| Secondary | Time to first relapse | 6 months | |
| Secondary | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) | 6 months | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) at the last visit. |
| Secondary | Change in timed 25 Foot Walk Test from baseline. | 1 month, 3 months, 6 months | Change in time taken to complete the timed 25 Foot Walk Test from baseline. |
| Secondary | Number of NMOSD attacked during follow-up | 6 months | Number of NMOSD treatment related to acute attack during follow-up. |
| Secondary | Change in serum GFAP levels from baseline | 1 month, 6 months | Change in serum GFAP levels from baseline to the last visit. |
| Secondary | Change in AQP4-ab titres from baseline | 1month, 6 months | Change in AQP4-ab titres from baseline to the last visit |
| Secondary | Change in serum NfL levels from baseline | 1 month, 6 months | Change in serum NfL levels from baseline to the last visit |
| Secondary | Change in Visual Acuity (VA) from baseline | 1 month, 6 months | Change in Visual Acuity (VA) at1 month 1, and 6 month. |
| Secondary | Changes in EQ-5D-5L scores from baseline | 6 months | Changes in EQ-5D scores from baseline to month 6(EQ-5D-5L: Minimum Score 5, Maximum score 25, lower scores mean a better quality of life). |
| Secondary | Change in retinal nerve fibre layer (RNFL) loss from baseline | 1 month,6 months | Change in retinal nerve fibre layer (RNFL) loss measured by optical coherence tomography (OCT) from baseline at month 1, month 6. |
| Secondary | Adverse reactions during treatment and follow-up | 6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06118398/registered